With some traditional drug companies starved for growth, Cramer thinks smaller biotechs may be in play.» Read More
Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.
July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.
July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales. Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter.
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
NEW YORK, June 20- In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.
June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago.
June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago. Achillion submitted additional data on the drug in September, but the FDA maintained the hold.
*Apple attracts heavy trading following stock split. *International Game Technology shares fly after Reuters report. NEW YORK, June 9- The Dow and S&P 500 ended at record highs again on Monday as more deal news raised enthusiasm for stocks, though Wall Street's fear gauge advanced.
U.S. stocks tallied slight gains on Monday, with benchmark indexes again closing at records.
Baupost Group appears to have made a nearly $1 billion off of Merck's deal to buy Idenix.
*Apple sees heavy trading following stock split. NEW YORK, June 9- U.S. stocks were nearly flat on Monday after the Dow and S&P 500 hit intraday record highs again on more deal news, while Wall Street's fear gauge rebounded.
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.
*Apple sees heavy trading following stock split. NEW YORK, June 9- U.S. stocks edged higher on Monday, pushing the Dow and S&P 500 to intraday record highs again after a series of deals, though Wall Street's fear gauge also bounced back. Merck& Co said it has agreed to buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion.
Some of Monday's midday movers:
*Apple sees heavy trading following stock split. NEW YORK, June 9- U.S. stocks advanced on Monday, boosted by a number of major acquisition deals, though gains were slight with key indexes continuing to hover around records. While Wall Street's upward trend looks intact, traders may need new catalysts to bid the market up further lest the momentum runs out of steam.
Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.
U.S. stock index futures pointed to a flat-to-lower open on Wall Street on Monday, despite upbeat data from China and Japan.
*Apple may see heavy action following stock split. NEW YORK, June 9- U.S. stock index futures pointed to modest losses at the open on Monday, as a rash of corporate deals weren't enough reason for investors to keep buying following a rally that has taken major indexes to repeated record highs.
Some of the names on the move ahead of the open.
*UBS cuts Idenix price target to $9 from $10. *UBS raises Celgene price target to $82 from $80. Reuters Station users, click. 1568.